{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:56:27Z","timestamp":1791597387358,"version":"4.3.4"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2022YFC2404605"],"award-info":[{"award-number":["2022YFC2404605"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Post-Marketing Clinical Research Special Project on Innovative Drug","award":["WKZX2023Cx020012"],"award-info":[{"award-number":["WKZX2023Cx020012"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172865"],"award-info":[{"award-number":["82172865"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023LZL002 and ZR2024MH007"],"award-info":[{"award-number":["ZR2023LZL002 and ZR2024MH007"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Research Special Fund of Wu Jieping Medical Foundation","award":["320.6750.2021-02-51 and 320.6750.2021-17-13"],"award-info":[{"award-number":["320.6750.2021-02-51 and 320.6750.2021-17-13"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-025-01716-9","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T05:17:57Z","timestamp":1766467077000},"page":"1416-1426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advances in Immunotherapy and Chemoradiotherapy Combination for Limited-Stage Small-Cell Lung Cancer: Current Landscape and Future Frontiers"],"prefix":"10.1007","volume":"27","author":[{"given":"Jingze","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"1716_CR1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.neo.2017.07.007","volume":"19","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Reid TR, Oronsky A, et al. What\u2019s new in SCLC? A review. Neoplasia. 2017;19:842\u20137. https:\/\/doi.org\/10.1016\/j.neo.2017.07.007.","journal-title":"Neoplasia"},{"key":"1716_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"key":"1716_CR3","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/cncr.29098","volume":"121","author":"LA Byers","year":"2015","unstructured":"Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2015;121:664\u201372. https:\/\/doi.org\/10.1002\/cncr.29098.","journal-title":"Cancer"},{"key":"1716_CR4","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1007\/s12094-023-03216-3","volume":"25","author":"R Garc\u00eda-Campelo","year":"2023","unstructured":"Garc\u00eda-Campelo R, Sullivan I, Arriola E, et al. SEOM-GECP clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022). Clin Transl Oncol. 2023;25:2679\u201391. https:\/\/doi.org\/10.1007\/s12094-023-03216-3.","journal-title":"Clin Transl Oncol"},{"key":"1716_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","volume":"32","author":"A-MC Dingemans","year":"2021","unstructured":"Dingemans A-MC, Fr\u00fch M, Ardizzoni A, et al. Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2021;32:839\u201353. https:\/\/doi.org\/10.1016\/j.annonc.2021.03.207.","journal-title":"Ann Oncol"},{"key":"1716_CR6","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","volume":"19","author":"AKP Ganti","year":"2021","unstructured":"Ganti AKP, Loo BW, Bassetti M, et al. Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:1441\u201364. https:\/\/doi.org\/10.6004\/jnccn.2021.0058.","journal-title":"J Natl Compr Canc Netw"},{"key":"1716_CR7","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/S1470-2045(17)30318-2","volume":"18","author":"C Faivre-Finn","year":"2017","unstructured":"Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18:1116\u201325. https:\/\/doi.org\/10.1016\/S1470-2045(17)30318-2.","journal-title":"Lancet Oncol"},{"key":"1716_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S1470-2045(20)30742-7","volume":"22","author":"BH Gr\u00f8nberg","year":"2021","unstructured":"Gr\u00f8nberg BH, Killingberg KT, Fl\u00f8tten \u00d8, et al. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22:321\u201331. https:\/\/doi.org\/10.1016\/S1470-2045(20)30742-7.","journal-title":"Lancet Oncol"},{"key":"1716_CR9","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1200\/JCO.22.01359","volume":"41","author":"J Bogart","year":"2023","unstructured":"Bogart J, Wang X, Masters G, et al. High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)\/RTOG 0538. JCO. 2023;41:2394\u2013402. https:\/\/doi.org\/10.1200\/JCO.22.01359.","journal-title":"JCO"},{"key":"1716_CR10","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1200\/JCO.20.00793","volume":"38","author":"CM Rudin","year":"2020","unstructured":"Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. JCO. 2020;38:2369\u201379. https:\/\/doi.org\/10.1200\/JCO.20.00793.","journal-title":"JCO"},{"key":"1716_CR11","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(19)32222-6.","journal-title":"Lancet"},{"key":"1716_CR12","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","volume":"23","author":"J Wang","year":"2022","unstructured":"Wang J, Zhou C, Yao W, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:739\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(22)00224-8.","journal-title":"Lancet Oncol"},{"key":"1716_CR13","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1809697.","journal-title":"N Engl J Med"},{"key":"1716_CR14","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer. N Engl J Med. 2017;377:1919\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1709937.","journal-title":"N Engl J Med"},{"key":"1716_CR15","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer. JCO. 2022;40:1301\u201311. https:\/\/doi.org\/10.1200\/JCO.21.01308.","journal-title":"JCO"},{"key":"1716_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.annonc.2021.09.011","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters S, Pujol J-L, Dafni U, et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy \u2013 results from the randomised phase II ETOP\/IFCT 4\u201312 STIMULI trial. Ann Oncol. 2022;33:67\u201379. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.011.","journal-title":"Ann Oncol"},{"key":"1716_CR17","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1200\/JCO.20.02212","volume":"39","author":"TK Owonikoko","year":"2021","unstructured":"Owonikoko TK, Park K, Govindan R, et al. Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451. JCO. 2021;39:1349\u201359. https:\/\/doi.org\/10.1200\/JCO.20.02212.","journal-title":"JCO"},{"key":"1716_CR18","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","volume":"391","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Spigel DR, Cho BC, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med. 2024;391:1313\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2404873.","journal-title":"N Engl J Med"},{"key":"1716_CR19","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1016\/j.cllc.2019.12.006","volume":"21","author":"S Senan","year":"2020","unstructured":"Senan S, Okamoto I, Lee G, et al. Design and rationale for a phase III, randomized, placebo-controlled trial of durvalumab with or without tremelimumab after concurrent chemoradiotherapy for patients with limited-stage small-cell lung cancer: the ADRIATIC study. Clin Lung Cancer. 2020;21:e84\u20138. https:\/\/doi.org\/10.1016\/j.cllc.2019.12.006.","journal-title":"Clin Lung Cancer"},{"key":"1716_CR20","doi-asserted-by":"publisher","first-page":"S1267","DOI":"10.1016\/j.annonc.2024.08.2324","volume":"35","author":"S Senan","year":"2024","unstructured":"Senan S, Spigel DR, Cho BC, et al. LBA81 durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial. Ann Oncol. 2024;35:S1267\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2324.","journal-title":"Ann Oncol"},{"key":"1716_CR21","unstructured":"NCCN Clinical Practice Guidelines in Oncology: 2025 Updates - The ASCO Post. Available at: https:\/\/ascopost.com\/issues\/may-25-2025\/nccn-clinical-practice-guidelines-in-oncology-2025-updates?utm_source=chatgpt.com; Stand: 22.08.2025"},{"key":"1716_CR22","doi-asserted-by":"publisher","first-page":"8098","DOI":"10.1200\/JCO.2024.42.16_suppl.8098","volume":"42","author":"P Zhang","year":"2024","unstructured":"Zhang P, Liu F, Wang D, et al. A randomized phase II study of toripalimab consolidation or observation after concurrent chemoradiotherapy in limited-stage small cell lung cancer. JCO. 2024;42:8098\u20138098. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8098.","journal-title":"JCO"},{"key":"1716_CR23","doi-asserted-by":"publisher","first-page":"S1067","DOI":"10.1016\/j.annonc.2024.08.1886","volume":"35","author":"Y Wu","year":"2024","unstructured":"Wu Y, Deng L, Wang J, et al. 1795P consolidation serplulimab following concurrent hypofractionated chemoradiotherapy for limited-stage SCLC: preliminary analysis of phase II ASTRUM-LC01 study. Ann Oncol. 2024;35:S1067. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.1886.","journal-title":"Ann Oncol"},{"key":"1716_CR24","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/ni944","volume":"4","author":"N Watanabe","year":"2003","unstructured":"Watanabe N, Gavrieli M, Sedy JR, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol. 2003;4:670\u20139. https:\/\/doi.org\/10.1038\/ni944.","journal-title":"Nat Immunol"},{"key":"1716_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.654960","volume":"12","author":"Z Ning","year":"2021","unstructured":"Ning Z, Liu K, Xiong H. Roles of BTLA in immunity and immune disorders. Front Immunol. 2021;12:654960. https:\/\/doi.org\/10.3389\/fimmu.2021.654960.","journal-title":"Front Immunol"},{"key":"1716_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.682007","volume":"11","author":"C Demerl\u00e9","year":"2021","unstructured":"Demerl\u00e9 C, Gorvel L, Olive D. BTLA-HVEM couple in health and diseases: insights for immunotherapy in lung cancer. Front Oncol. 2021;11:682007. https:\/\/doi.org\/10.3389\/fonc.2021.682007.","journal-title":"Front Oncol"},{"key":"1716_CR27","doi-asserted-by":"publisher","first-page":"8579","DOI":"10.1200\/JCO.2023.41.16_suppl.8579","volume":"41","author":"Y Cheng","year":"2023","unstructured":"Cheng Y, Wang J, Yu Y, et al. Phase I\/II combination study of tifcemalimab with toripalimab in patients with refractory extensive stage small cell lung cancer (ES-SCLC). JCO. 2023;41:8579\u20138579. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8579.","journal-title":"JCO"},{"key":"1716_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000957","volume":"8","author":"J-M Chauvin","year":"2020","unstructured":"Chauvin J-M, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020;8:e000957. https:\/\/doi.org\/10.1136\/jitc-2020-000957.","journal-title":"J Immunother Cancer"},{"key":"1716_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, et al. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16:101. https:\/\/doi.org\/10.1186\/s13045-023-01499-1.","journal-title":"J Hematol Oncol"},{"key":"1716_CR30","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1083\/jcb.200503113","volume":"170","author":"E Ladi","year":"2005","unstructured":"Ladi E, Nichols JT, Ge W, et al. The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands. J Cell Biol. 2005;170:983\u201392. https:\/\/doi.org\/10.1083\/jcb.200503113.","journal-title":"J Cell Biol"},{"key":"1716_CR31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","volume":"16","author":"CM Rudin","year":"2023","unstructured":"Rudin CM, Reck M, Johnson ML, et al. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer. J Hematol Oncol. 2023;16:66. https:\/\/doi.org\/10.1186\/s13045-023-01464-y.","journal-title":"J Hematol Oncol"},{"key":"1716_CR32","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1158\/2159-8290.CD-NB2023-0081","volume":"13","author":"L Davenport","year":"2023","unstructured":"Davenport L. Tarlatamab shows promise in SCLC. Cancer Discov. 2023;13:2494\u20132494. https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2023-0081.","journal-title":"Cancer Discov"},{"key":"1716_CR33","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"M-J Ahn","year":"2023","unstructured":"Ahn M-J, Cho BC, Felip E, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389:2063\u201375. https:\/\/doi.org\/10.1056\/NEJMoa2307980.","journal-title":"N Engl J Med"},{"key":"1716_CR34","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMoa2502099","volume":"393","author":"G Mountzios","year":"2025","unstructured":"Mountzios G, Sun L, Cho BC, et al. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med. 2025;393:349\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2502099.","journal-title":"N Engl J Med"},{"key":"1716_CR35","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1038\/s41591-024-03132-1","volume":"30","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Chen J, Zhang W, et al. Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial. Nat Med. 2024;30:2967\u201376. https:\/\/doi.org\/10.1038\/s41591-024-03132-1.","journal-title":"Nat Med"},{"key":"1716_CR36","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.jtho.2020.08.022","volume":"15","author":"JW Welsh","year":"2020","unstructured":"Welsh JW, Heymach JV, Guo C, et al. Phase 1\/2 trial of pembrolizumab and concurrent chemoradiation therapy for limited-stage SCLC. J Thorac Oncol. 2020;15:1919\u201327. https:\/\/doi.org\/10.1016\/j.jtho.2020.08.022.","journal-title":"J Thorac Oncol"},{"key":"1716_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejca.2022.03.034","volume":"169","author":"S Park","year":"2022","unstructured":"Park S, Noh JM, Choi Y-L, et al. Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer. Eur J Cancer. 2022;169:42\u201353. https:\/\/doi.org\/10.1016\/j.ejca.2022.03.034.","journal-title":"Eur J Cancer"},{"key":"1716_CR38","doi-asserted-by":"publisher","first-page":"S372","DOI":"10.1016\/j.jtho.2023.09.657","volume":"18","author":"X Wang","year":"2023","unstructured":"Wang X, Zhao Q, Huang W. P2.14-05 a phase II study of sintilimab combined with concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer: SINCE-01 trial. J Thorac Oncol. 2023;18:S372\u20133. https:\/\/doi.org\/10.1016\/j.jtho.2023.09.657.","journal-title":"J Thorac Oncol"},{"key":"1716_CR39","unstructured":"ELCC 2024: Adebrelimab with concurrent chemoradiation (cCRT) for limited-stage small cell lung cancer (LS-SCLC): Safety run-in results of a phase III trial. . Im Internet: https:\/\/clin.larvol.com\/abstract-detail\/ELCC%202024\/69383960; Stand: 17.08.2025"},{"key":"1716_CR40","unstructured":"ClinicalTrials.gov. A Prospective, Two Cohort, Multicenter Phase II Clinical Study of Envafolimab Combined With Concurrent Chemoradiotherapy and Immune Maintenance Therapy For Limited Stage Small Cell Lung Cancer. NCT05904015. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05904015. Accessed August 22, 2025."},{"key":"1716_CR41","unstructured":"ClinicalTrials.gov. A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of Serplulimab or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer. NCT05353257. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05353257. Accessed August 22, 2025."},{"key":"1716_CR42","doi-asserted-by":"publisher","first-page":"CT255","DOI":"10.1158\/1538-7445.AM2024-CT255","volume":"84","author":"Y Gong","year":"2024","unstructured":"Gong Y, Pang Q, Yu R, et al. Abstract CT255: advantIG-204: a phase 2, multicenter, randomized, 3-arm, open-label study investigating the preliminary efficacy and safety of ociperlimab (anti-TIGIT) + tislelizumab (anti-PD-1) + concurrent chemoradiotherapy (cCRT) in patients with untreated limited-stage small cell lung cancer (SCLC). Cancer Res. 2024;84:CT255\u2013CT255. https:\/\/doi.org\/10.1158\/1538-7445.AM2024-CT255.","journal-title":"Cancer Res"},{"key":"1716_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102986","volume":"9","author":"JD Bradley","year":"2024","unstructured":"Bradley JD, Sugawara S, Lee KHH, et al. LBA1 durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: final results from PACIFIC-2. ESMO Open. 2024;9:102986. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102986.","journal-title":"ESMO Open"},{"key":"1716_CR44","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.ijrobp.2024.08.013","volume":"120","author":"K Higgins","year":"2024","unstructured":"Higgins K, Hu C, Ross HJ, et al. Concurrent chemoradiation \u00b1 atezolizumab (atezo) in limited-stage small cell lung cancer (LS-SCLC): results of NRG oncology\/alliance LU005. Int J Radiat Oncol Biol Phys. 2024;120:S2. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.08.013.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1716_CR45","doi-asserted-by":"publisher","first-page":"e325","DOI":"10.1016\/j.cllc.2022.04.005","volume":"23","author":"A Rimner","year":"2022","unstructured":"Rimner A, Lai W-CV, Califano R, et al. Rationale and design of the phase 3 KEYLYNK-013 study of pembrolizumab with concurrent chemoradiotherapy followed by pembrolizumab with or without olaparib for limited-stage small-cell lung cancer. Clin Lung Cancer. 2022;23:e325\u20139. https:\/\/doi.org\/10.1016\/j.cllc.2022.04.005.","journal-title":"Clin Lung Cancer"},{"key":"1716_CR46","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ejca.2018.11.015","volume":"107","author":"DP Zandberg","year":"2019","unstructured":"Zandberg DP, Algazi AP, Jimeno A, et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: results from a single-arm, phase II study in patients with \u226525% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer. 2019;107:142\u201352. https:\/\/doi.org\/10.1016\/j.ejca.2018.11.015.","journal-title":"Eur J Cancer"},{"key":"1716_CR47","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41571-018-0119-7","volume":"16","author":"ED Brooks","year":"2019","unstructured":"Brooks ED, Chang JY. Time to abandon single-site irradiation for inducing abscopal effects. Nat Rev Clin Oncol. 2019;16:123\u201335. https:\/\/doi.org\/10.1038\/s41571-018-0119-7.","journal-title":"Nat Rev Clin Oncol"},{"key":"1716_CR48","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/NEJMra1608986","volume":"377","author":"DE Citrin","year":"2017","unstructured":"Citrin DE. Recent developments in radiotherapy. N Engl J Med. 2017;377:1065\u201375. https:\/\/doi.org\/10.1056\/NEJMra1608986.","journal-title":"N Engl J Med"},{"key":"1716_CR49","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.jtho.2017.04.014","volume":"12","author":"X Gong","year":"2017","unstructured":"Gong X, Li X, Jiang T, et al. Combined radiotherapy and anti\u2013PD-L1 antibody synergistically enhances antitumor effect in non-small cell lung cancer. J Thorac Oncol. 2017;12:1085\u201397. https:\/\/doi.org\/10.1016\/j.jtho.2017.04.014.","journal-title":"J Thorac Oncol"},{"key":"1716_CR50","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1158\/2326-6066.CIR-20-0968","volume":"9","author":"O Heath","year":"2021","unstructured":"Heath O, Berlato C, Maniati E, et al. Chemotherapy induces tumor-associated macrophages that aid adaptive immune responses in ovarian cancer. Cancer Immunol Res. 2021;9:665\u201381. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0968.","journal-title":"Cancer Immunol Res"},{"key":"1716_CR51","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1056\/NEJM199901283400403","volume":"340","author":"AT Turrisi","year":"1999","unstructured":"Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265\u201371. https:\/\/doi.org\/10.1056\/NEJM199901283400403.","journal-title":"N Engl J Med"},{"key":"1716_CR52","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S2213-2600(24)00189-9","volume":"12","author":"J Yu","year":"2024","unstructured":"Yu J, Jiang L, Zhao L, et al. High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial. Lancet Respir Med. 2024;12:799\u2013809. https:\/\/doi.org\/10.1016\/S2213-2600(24)00189-9.","journal-title":"Lancet Respir Med"},{"key":"1716_CR53","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1200\/JCO.2005.02.9793","volume":"24","author":"D De Ruysscher","year":"2006","unstructured":"De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. JCO. 2006;24:1057\u201363. https:\/\/doi.org\/10.1200\/JCO.2005.02.9793.","journal-title":"JCO"},{"key":"1716_CR54","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/annonc\/mdj094","volume":"17","author":"D De Ruysscher","year":"2006","unstructured":"De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, et al. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol. 2006;17:543\u201352. https:\/\/doi.org\/10.1093\/annonc\/mdj094.","journal-title":"Ann Oncol"},{"key":"1716_CR55","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.1200\/JCO.2004.01.178","volume":"22","author":"DB Fried","year":"2004","unstructured":"Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. JCO. 2004;22:4837\u201345. https:\/\/doi.org\/10.1200\/JCO.2004.01.178.","journal-title":"JCO"},{"key":"1716_CR56","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1093\/annonc\/mdw263","volume":"27","author":"D De Ruysscher","year":"2016","unstructured":"De Ruysscher D, Lueza B, Le P\u00e9choux C, et al. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Ann Oncol. 2016;27:1818\u201328. https:\/\/doi.org\/10.1093\/annonc\/mdw263.","journal-title":"Ann Oncol"},{"key":"1716_CR57","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ijrobp.2021.05.003","volume":"111","author":"B Qiu","year":"2021","unstructured":"Qiu B, Li Q, Liu J, et al. Moderately hypofractionated once-daily compared with twice-daily thoracic radiation therapy concurrently with etoposide and cisplatin in limited-stage small cell lung cancer: a multicenter, phase II, randomized trial. Int J Radiat Oncol Biol Phys. 2021;111:424\u201335. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.05.003.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1716_CR58","doi-asserted-by":"publisher","first-page":"S166","DOI":"10.1016\/j.jtho.2023.09.245","volume":"18","author":"N Bi","year":"2023","unstructured":"Bi N, Zhang T, Hu X, et al. MA18.03 preliminary safety and treatment data of a phase 3 trial: hypofractionated vs conventional fractionated concurrent chemoradiation for LS-SCLC. J Thorac Oncol. 2023;18:S166. https:\/\/doi.org\/10.1016\/j.jtho.2023.09.245.","journal-title":"J Thorac Oncol"},{"key":"1716_CR59","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/NEJM199908123410703","volume":"341","author":"A Aup\u00e9rin","year":"1999","unstructured":"Aup\u00e9rin A, Arriagada R, Pignon J-P, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med. 1999;341:476\u201384. https:\/\/doi.org\/10.1056\/NEJM199908123410703.","journal-title":"N Engl J Med"},{"key":"1716_CR60","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ctro.2021.06.009","volume":"30","author":"M Yan","year":"2021","unstructured":"Yan M, Toh TS, Lindsay PE, et al. Limited-stage small cell lung cancer: outcomes associated with prophylactic cranial irradiation over a 20-year period at the Princess Margaret Cancer Centre. Clin Transl Radiat Oncol. 2021;30:43\u20139. https:\/\/doi.org\/10.1016\/j.ctro.2021.06.009.","journal-title":"Clin Transl Radiat Oncol"},{"key":"1716_CR61","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(17)30230-9","volume":"18","author":"T Takahashi","year":"2017","unstructured":"Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:663\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(17)30230-9.","journal-title":"Lancet Oncol"},{"key":"1716_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.875488","volume":"13","author":"X Chu","year":"2022","unstructured":"Chu X, Niu L, Xiao G, et al. The long-term and short-term efficacy of immunotherapy in non-small cell lung cancer patients with brain metastases: a systematic review and meta-analysis. Front Immunol. 2022;13:875488. https:\/\/doi.org\/10.3389\/fimmu.2022.875488.","journal-title":"Front Immunol"},{"key":"1716_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107993","volume":"198","author":"A Levy","year":"2024","unstructured":"Levy A, Berghmans T, Koller M, et al. PRIMALung (EORTC-1901): prophylactic cerebral irradiation (PCI) or active brain MAgnetic resonance imaging (MRI) surveillance in small-cell lung cancer (SCLC) patients. Lung Cancer. 2024;198:107993. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107993.","journal-title":"Lung Cancer"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01716-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01716-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01716-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T07:24:46Z","timestamp":1766820286000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01716-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":63,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1716"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01716-9","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"22 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}